Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Ana Baramidze, Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Davit Giorgadze, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Yuntong Li, Debra A G McIntyre, Xue Jia, Javier Perez, Manika Kaul, Israel Lowy, Jean-Francois Pouliot, Stefanie Chua, Eric Kim, Frank Seebach, Heather Magnan
J Thorac Oncol 103980
摘要
摘要
INTRODUCTION: EMPOWER-Lung 3 Part 2 trial demonstrated significant survival benefits with cemiplimab plus chemotherapy versus chemotherapy in patients with previously untreated advanced NSCLC without EGFR, ALK, or ROS1 aberrations. Here, we report 5-year follow-up outcomes. METHODS: Patients were randomized 2:1 to receive cemiplimab (350 mg every 3 weeks for up to 108 weeks) or placebo, plus four cycles of chemotherapy. Primary endpoint was overall survival (OS); secondary endpoints included progression free survival (PFS) and objective response rate (ORR). RESULTS: This study randomized 466 patients to cemiplimab plus chemotherapy (n=312) or chemotherapy (n=154). After a median follow-up of 60.9 months, median OS was 21.1 months for cemiplimab plus chemotherapy versus 12.9 months for chemotherapy alone (hazard ratio [HR], 0.66 [95% CI: 0.53-0.83]; p = 0.0002); median PFS was 8.2 months versus 5.5 months (HR, 0.58 [95% CI: 0.47-0.72]; p < 0.0001); ORR was 43.6% versus 22.1%; and complete response was observed in 6.4% of patients (20/312) versus 0% (0/154), respectively. Five-year OS probability was 19.4% for cemiplimab plus chemotherapy versus 8.8% for chemotherapy. Efficacy was demonstrated in both squamous and nonsquamous histology. For 22.8% (71/312) patients who completed 36 cycles of cemiplimab treatment, OS probability was 57.3% at 3 years after treatment completion (approximately 5 years after randomization). Among the total study population, incidence of treatment-emergent adverse events of grade 3 or higher was 49.4% with cemiplimab plus chemotherapy and 32.7% with chemotherapy alone. CONCLUSIONS: With 5-year follow-up, cemiplimab plus chemotherapy continues to show durable long-term efficacy benefits versus chemotherapy with consistent safety profile, as first-line therapy for advanced NSCLC.
KM 提取结果
0 个 Figure · 0 个 KM 面板